April 16, 2024
Chugai Pharmaceutical’s bispecific antibody Vabysmo (faricimab) is heading towards a regulatory filing in Japan next year for a label expansion into angioid streaks now that the drug has hit the main goal in a relevant domestic study. The Roche group...read more